Primary Biliary Cirrhosis - Pipeline Review, H1 2018

January 2018 | 111 pages | ID: P9260FA2C13EN
Global Markets Direct

Abstracts

Primary Biliary Cirrhosis - Pipeline Review, H1 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Biliary Cirrhosis - Pipeline Review, H1 2018, provides an overview of the Primary Biliary Cirrhosis (Gastrointestinal) pipeline landscape.

Primary biliary cirrhosis is a chronic disease of the liver that slowly destroys the bile ducts within the liver. Symptoms include fatigue, itchy skin, dry eyes, jaundice, swollen feet and ankles, pain in the upper right portion of the abdomen and diarrhea. Predisposing factors include age and history of infections. Treatment includes bile acid sequestrants and liver transplantation.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Biliary Cirrhosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Biliary Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed and Preclinical stages are 2, 12, 1, 1, 1 and 1 respectively.

Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Biliary Cirrhosis (Gastrointestinal).
• The pipeline guide reviews pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Primary Biliary Cirrhosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Primary Biliary Cirrhosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Primary Biliary Cirrhosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Primary Biliary Cirrhosis - Overview
Primary Biliary Cirrhosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Primary Biliary Cirrhosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Primary Biliary Cirrhosis - Companies Involved in Therapeutics Development
Albireo Pharma Inc
Arena Pharmaceuticals Inc
Cadila Healthcare Ltd
CymaBay Therapeutics Inc
Dr. Falk Pharma GmbH
Eisai Co Ltd
Enanta Pharmaceuticals Inc
Genfit SA
GenKyoTex SA
Gilead Sciences Inc
GlaxoSmithKline Plc
Intercept Pharmaceuticals Inc
NGM Biopharmaceuticals Inc
Novartis AG
Tiziana Life Sciences Plc
Virobay Inc
Primary Biliary Cirrhosis - Drug Profiles
A-4250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-6011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EDP-305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elafibranor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etrasimod arginine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FFP-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
foralumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GKT-831 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GS-9674 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2330672 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NGM-282 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
obeticholic acid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
saroglitazar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seladelpar lysine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tropifexor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ursodiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBY-825 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZG-5216 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Primary Biliary Cirrhosis - Dormant Projects
Primary Biliary Cirrhosis - Product Development Milestones
Featured News & Press Releases
Nov 01, 2017: Intercept Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
Jun 27, 2017: Genkyotex Initiates Patient Enrollment into Phase 2 Trial of GKT831 in Primary Biliary Cholangitis
May 02, 2017: Genkyotex Announces FDA Approval of IND for Phase 2 Trial of GKT831 in Patients with Primary Biliary Cholangitis
Apr 19, 2017: Intercept Announces New Ocaliva (obeticholic acid) and INT-767 Data to be Presented at EASL 2017
Apr 05, 2017: Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress 2017
Feb 23, 2017: Zydus receives approval from USFDA to initiate Phase II clinical studies of Saroglitazar Magnesium in patients with Primary Biliary Cholangitis
Nov 04, 2016: GENFIT: FDA has officially cleared the IND to proceed with Phase II trial and evaluate elafibranor in PBC
Aug 17, 2016: New England Journal of Medicine Publishes Results of Phase 3 POISE Trial of Ocaliva (Obeticholic Acid) for the Treatment of PBC
May 27, 2016: FDA Grants Accelerated Approval to Ocaliva (Obeticholic Acid) for the Treatment of Patients with PBC
May 18, 2016: Intercept Announces Ocaliva (Obeticholic Acid) Data in PBC to be Presented at DDW 2016
Apr 14, 2016: New Analyses of the Phase 3 POISE Trial of Ocaliva (Obeticholic Acid) for the Treatment of PBC Presented at EASL
Apr 07, 2016: FDA Advisory Committee Unanimously Recommends Accelerated Approval of Ocaliva (obeticholic acid) for the Treatment of PBC
Mar 30, 2016: Intercept Announces New OCA Data in PBC and NASH to be Presented at EASL 2016
Feb 03, 2016: Fast Forward Pharmaceuticals Initiates Phase II Pilot Studies in Primary Biliary Cirrhosis and Crohn’s Disease with anti-CD40 Monoclonal Antibody
Dec 17, 2015: FDA Extends PDUFA Date for Obeticholic Acid for the Treatment of PBC
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Primary Biliary Cirrhosis, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Primary Biliary Cirrhosis - Pipeline by Albireo Pharma Inc, H1 2018
Primary Biliary Cirrhosis - Pipeline by Arena Pharmaceuticals Inc, H1 2018
Primary Biliary Cirrhosis - Pipeline by Cadila Healthcare Ltd, H1 2018
Primary Biliary Cirrhosis - Pipeline by CymaBay Therapeutics Inc, H1 2018
Primary Biliary Cirrhosis - Pipeline by Dr. Falk Pharma GmbH, H1 2018
Primary Biliary Cirrhosis - Pipeline by Eisai Co Ltd, H1 2018
Primary Biliary Cirrhosis - Pipeline by Enanta Pharmaceuticals Inc, H1 2018
Primary Biliary Cirrhosis - Pipeline by Genfit SA, H1 2018
Primary Biliary Cirrhosis - Pipeline by GenKyoTex SA, H1 2018
Primary Biliary Cirrhosis - Pipeline by Gilead Sciences Inc, H1 2018
Primary Biliary Cirrhosis - Pipeline by GlaxoSmithKline Plc, H1 2018
Primary Biliary Cirrhosis - Pipeline by Intercept Pharmaceuticals Inc, H1 2018
Primary Biliary Cirrhosis - Pipeline by NGM Biopharmaceuticals Inc, H1 2018
Primary Biliary Cirrhosis - Pipeline by Novartis AG, H1 2018
Primary Biliary Cirrhosis - Pipeline by Tiziana Life Sciences Plc, H1 2018
Primary Biliary Cirrhosis - Pipeline by Virobay Inc, H1 2018
Primary Biliary Cirrhosis - Dormant Projects, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development for Primary Biliary Cirrhosis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Albireo Pharma Inc
Arena Pharmaceuticals Inc
Cadila Healthcare Ltd
CymaBay Therapeutics Inc
Dr. Falk Pharma GmbH
Eisai Co Ltd
Enanta Pharmaceuticals Inc
Genfit SA
GenKyoTex SA
Gilead Sciences Inc
GlaxoSmithKline Plc
Intercept Pharmaceuticals Inc
NGM Biopharmaceuticals Inc
Novartis AG
Tiziana Life Sciences Plc
Virobay Inc